Kennedy Capital Management’s BioNTech BNTX Stock Holding History

Kennedy Capital Management’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.19M	Buy	23,511 +1,598	+7%	+$150K	0.04%	443
2026 Q1	$1.95M	Buy	21,913 +848	+4%	+$87.1K	0.04%	422
2025 Q4	$2.01M	Buy	21,065 +134	+0.6%	+$13.5K	0.04%	425
2025 Q3	$2.06M	Buy	20,931 +4,509	+27%	+$482K	0.05%	445
2025 Q2	$1.75M	Buy	16,422 +127	+0.8%	+$12.8K	0.04%	457
2025 Q1	$1.48M	Buy	16,295 +2,475	+18%	+$277K	0.04%	464
2024 Q4	$1.57M	Buy	13,820 +9,964	+258%	+$1.14M	0.04%	550
2024 Q3	$458K	Buy	+3,856	New	+$354K	0.01%	640

Other funds holding BNTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $22.1B AUM 6.81% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

GSK plc London $602M AUM

Kennedy Capital Management's BNTX Position: Q2 2026 in Review

Kennedy Capital Management increased its BioNTech (BNTX) stake by 7.3% in Q2 2026, buying an estimated $150K and bringing the position to 23,511 shares worth $2.19M. The position accounts for 0.04% of the portfolio, ranked #443.

Kennedy Capital Management first reported a position in BNTX in Q3 2024 and has held it in 8 quarters since. 282 funds tracked by Wall St. Rank hold BNTX as of Q2 2026.

Kennedy Capital Management held 23,511 shares of BioNTech worth $2.19M as of Q2 2026.
Kennedy Capital Management bought 1,598 BioNTech shares in Q2 2026, an estimated $150K.
BioNTech made up 0.04% of Kennedy Capital Management's portfolio in Q2 2026, its #443 holding.
Kennedy Capital Management first reported a position in BioNTech in Q3 2024 and has held it in 8 quarters since.
282 funds tracked by Wall St. Rank held BioNTech as of Q2 2026.

Based on Kennedy Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.